TrialFrontiers in endocrinology2021

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.

Xu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.